System secures USD 20M for peptide expansion
The global peptide therapeutics market is projected to reach an estimated USD 163 billion in 2026.
USA – System, a San Francisco–based, peptide-native platform, has secured USD 20 million in new funding to expand its vertically integrated peptide platform and widen access to peptide-based treatments.
The company announced the funding raise, with participation from Patron Fund, Will Ventures, Vine, Courtside, Daybreak, SV Angel and RiverPark Ventures.
According to System, the capital will fund infrastructure expansion, broaden consumer access to regulated peptide therapies, and continue building out its end‑to‑end supply chain as the category moves into a more regulated era.
Despite rising adoption of peptides for uses ranging from anti‑aging and skin rejuvenation to weight management, muscle growth, recovery and energy enhancement, these treatments have historically been costly, inconsistently regulated and largely inaccessible outside niche or concierge‑medicine settings.
Adam Steinle, Founder and CEO of System, stated, “My vision was never to be another DTC telehealth brand, but to own more of the stack and build the foundation this category needs as it moves into the mainstream.”
“We want to be category definers and the solution Americans use and trust for their long-term health. This funding signals that we’re building a company that is filling the gap between concierge clinics and research-grade access that no single platform currently owns.”
Currently, there is a rapidly expanding peptide market, projected to reach USD 163 billion in 2026, up from around USD 140 billion in 2025, driven by growing interest in longevity, wellness and personalized health solutions.
The funding comes as US regulatory discussions around injectable peptides intensify.
On July 23–24,2026, the US Food and Drug Administration (FDA) voted to recommend adding six previously unapproved injectable peptides to a bulk drug substance list, a move that, if formally adopted, could allow licensed compounding pharmacies to legally prepare these compounds for patients.
System frames this as a shift from the “edges of wellness” toward a more regulated, mainstream distribution model that aligns with rising consumer interest in peptide therapies.
At the time of the vote, FDA scientists reportedly cautioned against approval, citing insufficient safety and efficacy data and limited human studies for several of the injectable solutions under consideration.
System positions itself as infrastructure for the peptide category, aiming to become a trusted, peptide-native platform that connects consumers with US-licensed clinicians and pharmacy-grade compounded treatments.
Its model pairs patients with clinicians who review individual health histories and prescribe personalized peptide protocols; prescribed treatments are then compounded by certified US pharmacies and shipped directly to consumers.
To strengthen control and transparency, System plans to acquire more links in the supply chain, including integrating a compounding pharmacy into its network and pursuing raw‑ingredient (API) manufacturing.
The company emphasizes third‑party lab testing of every product, background checks and National Practitioner Data Bank (NPDB) reviews of clinicians, and sourcing exclusively from FDA‑registered US compounding pharmacies.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.
